RESUMEN
BACKGROUND: Information on genital wart incidence in adolescents and young adults before human papillomavirus (HPV) vaccination is important for understanding the impact of the vaccine on the epidemiology of this early outcome of HPV infection. METHODS: The study population included 11- to 29-year-old enrollees of Northern California Kaiser Permanente between July 1, 2000, and July 1, 2005, before the availability of the HPV vaccine. We identified genital warts with an algorithm combining genital wart-specific International Classification of Diseases, Ninth Revision, Clinical Modification codes (078.10, 078.11, and 078.19) with physician-recorded anatomic locations. We calculated sex- and age-specific incidence rates of genital warts and described the specific anatomic location of presentation, as well as recurrences of genital warts. RESULTS: We identified 1,682 cases of genital warts among 181,264 individuals. The incidence rate was highest among women (6.3/1000 person-years) and men (2.9/1000 person-years) aged 20 to 24 years old. Among women (n = 96,792), 63.4% of the 1240 incident genital wart cases occurred on the vulva and 21.1% on the cervix. Among men (n = 84,472), 91.6% of the 442 incident genital wart cases did not have a specific anatomic location recorded. Most people with an incident genital wart diagnosis (87.2%) did not have a recurrence during the observation period. CONCLUSIONS: Our study found that the incidence of genital warts was highest among persons aged 20 to 24 years using a unique method to identify the location of the wart. Information on incidence of genital warts before vaccine use provides baseline data that can be used to measure HPV vaccine impact.
Asunto(s)
Condiloma Acuminado/prevención & control , Papillomaviridae/inmunología , Enfermedades del Pene/prevención & control , Enfermedades Uretrales/prevención & control , Enfermedades del Cuello del Útero/prevención & control , Enfermedades Vaginales/prevención & control , Enfermedades de la Vulva/prevención & control , Adolescente , Adulto , California/epidemiología , Niño , Estudios de Cohortes , Condiloma Acuminado/clasificación , Condiloma Acuminado/epidemiología , Condiloma Acuminado/virología , Prestación Integrada de Atención de Salud , Femenino , Humanos , Incidencia , Masculino , Vacunas contra Papillomavirus , Enfermedades del Pene/clasificación , Enfermedades del Pene/virología , Enfermedades Virales de Transmisión Sexual/clasificación , Enfermedades Virales de Transmisión Sexual/epidemiología , Enfermedades Virales de Transmisión Sexual/prevención & control , Enfermedades Virales de Transmisión Sexual/virología , Enfermedades Uretrales/clasificación , Enfermedades Uretrales/virología , Enfermedades del Cuello del Útero/clasificación , Enfermedades del Cuello del Útero/virología , Vacunación , Enfermedades Vaginales/clasificación , Enfermedades Vaginales/virología , Enfermedades de la Vulva/clasificación , Enfermedades de la Vulva/virología , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVES: Genital warts represent benign epithelial proliferations induced by human papillomavirus. The goal of treatment is the clearance of visible warts. Different regimens are available. Flashlamp-pumped pulsed dye laser (FPDL) represents one of many treatment options for the management of viral warts (verrucae vulgares), its effectiveness being comparable with that of conventional therapies. We evaluated the effectivity of FPDL light for the treatment of genital warts. STUDY DESIGN/MATERIALS AND METHODS: A prospective study was performed to examine the efficacy of FPDL in untreated genital warts in which 22 patients were included. RESULTS: All patients showed complete remission after 1.59 (1-5) laser sessions and no scarring was observed. CONCLUSIONS: This study demonstrate that FPDL is a simple and safe, cost and time saving alternative treatment option for genital warts and should be listed in genital warts treatment guidelines.